---
title: "What To Expect From STAAR Surgical’s (STAA) Q2 Earnings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295477914.md"
description: "STAAR Surgical (STAA) reports Q2 earnings after market close Wednesday. Last quarter, the company beat revenue and EPS estimates with $93.52 million in sales, up 120% YoY. This quarter, analysts expect another 104% revenue growth. While peers like Inspire Medical Systems and Integer Holdings recently beat expectations, STAAR has missed estimates multiple times over two years. The stock is down 8.9% recently, trading below its $28.70 average analyst target."
datetime: "2026-08-11T03:04:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295477914.md)
  - [en](https://longbridge.com/en/news/295477914.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295477914.md)
generator: "portal-rs"
---

# What To Expect From STAAR Surgical’s (STAA) Q2 Earnings

Medical lens company STAAR Surgical will be reporting earnings this Wednesday after market hours. Here’s what investors should know.

STAAR Surgical beat analysts’ revenue expectations last quarter, reporting revenues of $93.52 million, up 120% year on year. It was an incredible quarter for the company, with a beat of analysts’ EPS estimates.

Is STAAR Surgical a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting STAAR Surgical’s revenue to grow 104% year on year, a reversal from the 55.2% decrease it recorded in the same quarter last year.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. STAAR Surgical has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at STAAR Surgical’s peers in the medical devices & supplies - specialty segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Inspire Medical Systems’s revenues decreased 7.6% year on year, beating analysts’ expectations by 3%, and Integer Holdings reported a revenue decline of 2.6%, topping estimates by 3%. Inspire Medical Systems traded up 22.8% following the results while Integer Holdings was also up 3.2%.

Read our full analysis of Inspire Medical Systems’s results here and Integer Holdings’s results here.

There has been positive sentiment among investors in the medical devices & supplies - specialty segment, with share prices up 3.7% on average over the last month. STAAR Surgical is down 8.9% during the same time and is heading into earnings with an average analyst price target of $28.70 (compared to the current share price of $25.31).

**WHILE YOU’RE HERE: The Next Palantir?** One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this.

### Related Stocks

- [STAA.US](https://longbridge.com/en/quote/STAA.US.md)
- [INSP.US](https://longbridge.com/en/quote/INSP.US.md)
- [ITGR.US](https://longbridge.com/en/quote/ITGR.US.md)
- [PLTR.US](https://longbridge.com/en/quote/PLTR.US.md)

## Related News & Research

- [Defender Capital LLC. Has $12.37 Million Position in STAAR Surgical Company $STAA](https://longbridge.com/en/news/295503435.md)
- [How Investors Are Reacting To STAAR Surgical (STAA) Formalizing Warren Foust’s CEO Role And Leadership Structure](https://longbridge.com/en/news/295332182.md)
- [KKR Stock Outlook: $9B UGI Bid, Integer Deal and Record Q2 Earnings](https://longbridge.com/en/news/296703831.md)
- [07:52 ETAre ITGR, VREX, HZO, SYNA Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/296783520.md)
- [ITGR Investors Have Opportunity to Join Integer Holdings Corporation Fraud Investigation with SBS Law](https://longbridge.com/en/news/296706676.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**